| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
| Targets |
Dihydrojasmone exhibits antagonist activity on the human OR5K1 receptor. It potentiates the antifungal activity of terbinafine by affecting the functionality of the plasma membrane in dermatophytes. It has anti-inflammatory and anti-cancer attributes.
|
|---|---|
| ln Vitro |
In vitro, dihydrojasmone demonstrates antagonist activity on the human OR5K1 receptor. In an assay conducted using HEK293 cells, the compound demonstrated inhibition of the response induced by 2,6-dimethylpyrazine at a concentration of 100 µM, with the observed inhibition being equal to or greater than 40.0%.
|
| ln Vivo |
In vivo, dihydrojasmone has been studied for its anti-inflammatory and anti-cancer attributes. It exhibits notable potential in the treatment of skin ailments and as a prospective therapeutic intervention for specific cancer variations. It has been studied for its effects on aphid behavior at the plant-aphid interface.
|
| Enzyme Assay |
In vitro receptor binding assays for dihydrojasmone typically use membrane preparations from cells expressing the human OR5K1 receptor. Radiolabeled ligands are displaced by increasing concentrations of the compound to determine binding affinity. Functional assays measure the compound's ability to inhibit receptor-mediated signaling.
|
| Cell Assay |
Cell-based assays for dihydrojasmone involve treating HEK293 cells expressing OR5K1 with the compound and measuring receptor activity. Calcium mobilization or other signaling readouts are measured. The compound's ability to inhibit agonist-induced responses is quantified.
|
| Animal Protocol |
In vivo animal studies for dihydrojasmone typically involve application to host plants to study aphid behavioral responses. The compound's effects on insect behavior and plant-insect interactions are assessed. Anti-inflammatory and anti-cancer effects are studied in appropriate animal models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of dihydrojasmone are not well-characterized for therapeutic applications. The compound is a small lipophilic molecule. It is absorbed and distributed to tissues. Metabolism occurs in the liver. It is a constituent of bergamot oil.
|
| Toxicity/Toxicokinetics |
Dihydrojasmone is generally considered to have low toxicity as a fragrance compound. It is a synthetic fragrance compound. High doses may cause mild irritation. Appropriate safety precautions should be taken when handling the compound.
|
| References | |
| Additional Infomation |
3-Methyl-2-pentylcyclopent-2-en-1-one is a cyclic ketone.
Dihydrojasmone is a synthetic fragrance compound with anti-inflammatory and anti-cancer attributes. It is a constituent of bergamot oil. It is being investigated for its potential therapeutic applications in skin ailments and cancer. It is not currently approved for therapeutic use. |
| Molecular Formula |
C11H18O
|
|---|---|
| Molecular Weight |
166.26
|
| Exact Mass |
166.136
|
| CAS # |
1128-08-1
|
| PubChem CID |
62378
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
0.916 g/mL at 25 °C(lit.)
|
| Boiling Point |
120-121 °C12 mm Hg(lit.)
|
| Flash Point |
230 °F
|
| Vapour Pressure |
0.0575mmHg at 25°C
|
| Index of Refraction |
n20/D 1.479(lit.)
|
| LogP |
3.246
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
12
|
| Complexity |
201
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCC1=C(C)CCC1=O
|
| InChi Key |
YCIXWYOBMVNGTB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H18O/c1-3-4-5-6-10-9(2)7-8-11(10)12/h3-8H2,1-2H3
|
| Chemical Name |
3-methyl-2-pentylcyclopent-2-en-1-one
|
| Synonyms |
BRN 1906471; AI3-15185; Dihydrojasmone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~601.47 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (15.04 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (15.04 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (15.04 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.0147 mL | 30.0734 mL | 60.1468 mL | |
| 5 mM | 1.2029 mL | 6.0147 mL | 12.0294 mL | |
| 10 mM | 0.6015 mL | 3.0073 mL | 6.0147 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
